Speaker Profile

Ph.D., Medical Science Liaison, Jounce Therapeutics

Biography
Lee Kozakiewicz Rafsky, Ph.D. is an immunologist by training and is currently serving as the Medical Science Liaison at Jounce Therapeutics, a Cambridge-based biotech company focusing on the early stage development of new medicines for immuno-oncology. Before joining Jounce, she served as Medical Science Liaison at various pharmaceutical companies, including AbbVie Pharmaceuticals, Allergan plc, and Kythera Biopharmaceuticals, where she supported medical affairs activities for various commercialized therapies and drug launches. Prior to becoming an MSL, she earned her Ph.D. in the Department of Microbiology & Immunology at Albert Einstein College of Medicine, where she studied the role of B cells and the humoral response during Mycobacterium tuberculosis infection and BCG vaccination. Following completion of her doctoral defense, Lee did a postdoctoral fellowship in the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai School, where her research focused on myeloid derived suppressor cell-mediated suppression of antitumor T cell immune responses. She holds a B.A. in Biology from Colby College.


Immunotherapy Showcase:
Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach.

 Session Abstract – PMWC 2020 Silicon Valley


The PMWC 2020 Immunotherapy Showcase will provide a 15-minute time slot for selected immunotherapy companies to present their latest technologies and advancements to an audience of leading investors, potential clients, and partners. We will hear from companies building new cell-based immunotherapies, work in the growing area of cancer vaccines, that help understand the relevance of the tumor microenvironment, accelerate the patient selection process, or otherwise work towards overcoming to challenges related to therapeutic discovery.